Drug Trial Radar · NCT07391566
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.
Conditions
- Metastatic Colorectal Cancer (mCRC)
Interventions
LPM6690176Drug
LPM6690176 orally.
BevacizumabBiological
Bevacizumab intravenously
FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)Drug
FOLFIRI intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Dose-limiting toxicities (DLTs)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
- Phase Ib: Maximum tolerated dose (MTD)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
- Phase 1b: Recommended Phase 2 Dose (RP2D)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
- Phase 2: Overall response rate (ORR)Time frame: Approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.